Skip to content
logo MSD Oncology Clinical Trials
  • Início
  • Estudos
    • Menu principal
    • Visão geral do teste
    • Bexiga
    • Cabeça e Pescoço
    • Colorretal
    • Esofágico
    • Fígado e via Biliar
    • Gástrico
    • Ginecológico
    • Hematológico
    • Mama
    • Melanoma
    • Pediátrico
    • Próstata
    • Pulmão
    • Rim
    • Tumores Sólidos
  • Sobre
  • Perguntas frequentes
  • Para Profissionais Da Saúde
  • Português (BR)
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Study Keyword: Intracellular Adhesion Molecule-1

Substudy 02C is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.

The goal of substudy 02C is to evaluate the safety and efficacy of investigational treatment arms in participants with Stage III melanoma who are candidates for neoadjuvant therapy to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available.

Study Keyword: Intracellular Adhesion Molecule-1

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy

March 10, 2022

By Support_Clique

Substudy 02C is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of

Eficácia, segurança e tolerabilidade de V937 administrado por via intravenosa ou intratumoral com pembrolizumabe versus pembrolizumabe isoladamente em participantes com melanoma avançado/metastático

March 10, 2022

By Support_Clique

This is a Phase 2 study to assess the efficacy, safety, and tolerability of V937 administered both intratumorally (ITu) and intravenously (IV) as combination therapy with pembrolizumab (MK-3475) versus pembrolizumab alone

logo-white MSD Oncology Clinical Trials
  • Política de privacidade MSD
  • Termos de uso
  • Preferências de cookies
  • Acessibilidade

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

Acessibilidade

Acessibilidade